Serum Institute of India is the vaccine producer that will invest 50 million pounds ($68.24 million) in Oxford Biomedica, one of the COVID-19 vaccine manufacturers for drug major AstraZeneca, the British cell therapy firm said.

• Overnight Stock Market Movements: Key Developments 
• KPI Green Energy Shares Rally 5% on Bagging 120 MW Order 
• Surya Roshni Rises 2.7% on Demerger Reports, US Orders
• Benchmark Indices Fell 200 Points from day High
• Apollo Micro Systems Jumps 9% on Record FY26 Profit

The proceeds of the transaction will be used to fund the development of the fallow area at Oxbox, the group’s 84,000 sq. ft manufacturing facility based in Oxford, UK, into a flexible advanced manufacturing space and the validation of several independent cGMP suites, expected to come online in mid-2023.